GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Inventory-to-Revenue

Biomerica (Biomerica) Inventory-to-Revenue : 1.95 (As of Feb. 2024)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Biomerica's Average Total Inventories for the quarter that ended in Feb. 2024 was $1.99 Mil. Biomerica's Revenue for the three months ended in Feb. 2024 was $1.02 Mil. Biomerica's Inventory-to-Revenue for the quarter that ended in Feb. 2024 was 1.95.

Biomerica's Inventory-to-Revenue for the quarter that ended in Feb. 2024 increased from Nov. 2023 (1.19) to Nov. 2023 (1.95)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Biomerica's Days Inventory for the three months ended in Feb. 2024 was 155.34.

Inventory Turnover measures how fast the company turns over its inventory within a year. Biomerica's Inventory Turnover for the quarter that ended in Feb. 2024 was 0.59.


Biomerica Inventory-to-Revenue Historical Data

The historical data trend for Biomerica's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica Inventory-to-Revenue Chart

Biomerica Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.37 0.42 0.15 0.42

Biomerica Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 1.86 1.15 1.19 1.95

Competitive Comparison of Biomerica's Inventory-to-Revenue

For the Medical Devices subindustry, Biomerica's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica's Inventory-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biomerica's Inventory-to-Revenue falls into.



Biomerica Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biomerica's Inventory-to-Revenue for the fiscal year that ended in May. 2023 is calculated as

Inventory-to-Revenue (A: May. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: May. 2022 ) + Total Inventories (A: May. 2023 )) / count ) / Revenue (A: May. 2023 )
=( (2.416 + 2.056) / 2 ) / 5.339
=2.236 / 5.339
=0.42

Biomerica's Inventory-to-Revenue for the quarter that ended in Feb. 2024 is calculated as

Inventory-to-Revenue (Q: Feb. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Nov. 2023 ) + Total Inventories (Q: Feb. 2024 )) / count ) / Revenue (Q: Feb. 2024 )
=( (1.841 + 2.129) / 2 ) / 1.017
=1.985 / 1.017
=1.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomerica  (NAS:BMRA) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Biomerica's Days Inventory for the three months ended in Feb. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Feb. 2024 )/Cost of Goods Sold (Q: Feb. 2024 )*Days in Period
=1.985/1.166*365 / 4
=155.34

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Biomerica's Inventory Turnover for the quarter that ended in Feb. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Feb. 2024 ) / Average Total Inventories (Q: Feb. 2024 )
=1.166 / 1.985
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomerica Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biomerica's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663